Menu
X
    Madhura Dethe
  • Date: November 23, 2020
    • Categories: Health

BioShin registers first patient into its BHV3000-310 regional study

BioShin Limited has reportedly made an announcement disclosing the enrollment of first patient in its BHV3000-310 multi-center and regional study, being carried out in the territories of Korea and China. A randomized, double-blind trial, the study focuses on the evaluation of the efficacy and safety of rimegepant application in the acute treatment of migraine.



As explained by Prof. Yu Shengyuan, the Chief of Neurology, PLA General Hospital, migraine is a serious and common disease that impacts human health. According to WHO’s 2013 Global Burden of Disease Survey, migraine is the first cause of disability under 50s and the third most common human disease, requiring the availability of safe, new, and effective treatment alternatives for the improvement of patients’ lives of patients, added Shengyuan. The Neurology Chief rightly believes that rimegepant will be a welcome treatment option for patients and is encouraged to advance a step ahead for the introduction to patients in Asia.



For the uninitiated, BioShin Limited is a privately held biopharmaceutical company progressing its Biohaven clinical portfolio in the Asia-Pacific. The company reportedly holds rights for all of the region, inclusive of New Zealand and Australia, except Japan. BioShin’s neuroinnovation portfolio comprises rimegepant (NURTEC ODT) approved by the U.S. Food and Drug Administration for the acute treatment of migraine, in addition to an extensive pipeline of late-stage product candidates that spread across an array of three distinct mechanistic platforms.



According to BioShin’s CEO, Karl Lintel, M.D., the company is thrilled to have begun enrollment in its BHV300-310 study. Rimegepant was rolled out in March 2020 in the United States where the company’s differentiated profile with a long-half life and a rapid onset of action is being recognized by providers and patients as a significant new treatment for over two decades for the acute treatment of migraine, added Lintel. Further, BioShin believes that rimegepant will meet the unmet medical requirements of migraine patients in the Asia-Pacific, as it is doing in the United States, stated Lintel.



 



Source Credits:



https://www.globenewswire.com/news-release/2020/11/23/2131359/0/en/BioShin-enrolls-first-patient-into-an-Asia-Pacific-regional-multi-center-phase-III-clinical-trial-of-rimegepant-BHV-3000-for-the-acute-treatment-of-migraine.html
Madhura Dethe:

Having pursued a post graduate degree in English Literature, Madhura’s interest naturally drifted toward writing. Presently, she works as an associate content writer for lunchwithapunch.com and pens down insightful articles on healthcare, technology, and business trends. Her other interests comprise reading, sketching, and classical dance.
    Related Post